Glooko announced today that it entered into a partnership with Sanofi to integrate a connected device for insulin pens into its digital platform.
SoloSmart, a single-piece, add-on connected device works with Sanofi’s SoloStar and DoubleStar insulin injection pens. It records the insulin dose, date and time of injection. Through this partnership, the company’s can offer data visualization through the Glooko app. Patients can share data with healthcare professionals for connected care in their diabetes management.
According to a news release, Sanofi aims to utilize Glooko’s global footprint spanning over 8,000 clinics. It seeks to increase the accessibility of digital solutions in each country where it makes SoloSmart available.
SoloSmart currently remains unapproved for marketing in the U.S. Sanofi said it is currently integrating the technology into Glooko’s platform. It plans to gradually roll out this combined technology across several countries later in 2023. Sanofi noted that it plans to offer the solution in English language and other local languages.
“We are very pleased to announce our partnership with Sanofi, as this agreement represents the first substantial digital health collaboration between our two companies,” said Russ Johannesson, CEO, Glooko. “Glooko is the first global diabetes data management platform to launch with SoloSmart, something our team is particularly proud of. This will allow us to further expand our global reach aiming to provide best-in-class technologies that can benefit the lives of people with diabetes.”
What the future holds for the Glooko-Sanofi partnership
Glooko and Sanofi also retain the option to further expand their launch beyond the initial geographic scope.
Once the companies complete integration, SoloStar and DoubleStar users can add new capabilities to their diabetes management regimen. They can add the insulin dosing tracking and timing to the Glooko app’s functionality.
The companies said the combination of technologies can help users visualize the correlation between insulin dose and blood glucose values. Other uses for the tracking data include food tracking, exercise metrics, weight and blood pressure. These can create actional insights for people with diabetes to approach their care in a more personalized way.
“At Sanofi, we believe that we will deliver value to people living with diabetes by building an ecosystem with local and global partners. With Biocorp, SoloSmart’s manufacturer, Glooko, a leading digital health solution that supports patients and health care partners, and local partners, we aim to improve daily management for individuals living with diabetes,” said Jared Josleyn, Sanofi global head of digital healthcare. “For 100 years, Sanofi has been at the forefront of managing diabetes. We continue to build on this heritage with a vision and commitment to help transform diabetes care for 537 million people living with diabetes around the world.”